← Back

Sichuan Huiyu Pharmaceutical Co Ltd

Sichuan Huiyu Pharmaceutical Co., Ltd. researches, develops, produces, and sells anti-tumor injections in China and internationally. Its injection drug products include pemetrexed disodium, methotrexate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, amifostine, levofolate calcium, thiotepa, fulvestrant, and milrinone. The company also offers moroxydine sodium chloride, fluorouracil, sodium thiosulfate, acetylcysteine, nimodipine, dihydroxypropyltheophylline, cisatracurium besylate, cladribine, sodium carbosulfan, octreotide acetate, mesobamo, doxorubicin, leucovorin calcium, famotidine, etoposide, polymyxin B sulfate, melphalan hydrochloride, teicoplanin, epirubicin hydrochloride, gemcitabine hydrochloride, cytarabine, voriconazole, roxatidine acetate hydrochloride, and bortezomib. Incorporated in 2010, it is headquartered in Neijiang, China.

Country
Price · split & dividend adjusted
News & notes moving 688553.CG
688553.CG

Huiyu Pharmaceutical Releases 2026 Interim Report with Net Profit of 57.6486 Million Yuan

Huiyu Pharmaceutical released its 2026 interim report. The company's total operating revenue was 552 million yuan, net profit attributable to the parent company was 57.6486 million yuan, and net cash inflow from operating activities was 91.5207 million yuan. The company's latest asset-liability ratio was 28.56 percent, up 2.05 percentage points from the previous quarter and up 4.91 percentage points from the same period last year. The latest gross margin was 76.74 percent, down 2.43 percentage points from the previous quarter and down 2.66 percentage points from the same period last year. The latest return on equity was 1.55 percent. Diluted earnings per share were 0.09 yuan. The latest total asset turnover was 0.11 times, and the latest inventory turnover was 0.45 times, down 8.71 percent from the same period last year. The company had 16,500 shareholders, and the top ten shareholders held 319 million shares, accounting for 50.95 percent of total share capital.
688553.CG
Jiemian·28dRead more →
Biotech & Genomic Medicine▲3

Huiyu Pharmaceutical's HY07121 for Injection Receives Clinical Trial Approval

Huiyu Pharmaceutical announced that its wholly-owned subsidiary Huiyu Haiyue has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial for HY07121 for injection, administered subcutaneously, for the treatment of advanced solid tumors has been approved. The drug is an anti-PD-1, anti-TIGIT, IL-15/IL-15Rα triple-target antibody fusion protein, classified as a Class 1 innovative therapeutic biological product, aimed at improving patient convenience and reducing side effects. As of the announcement date, no similar product has been marketed.
688553.CG ▲
Biotech & Genomic Medicine
CLS·31dRead more →
688553.CG▲

Huiyu Pharmaceutical receives 5 million yuan in government grants

Huiyu Pharmaceutical recently received government grants totaling 5 million yuan. The grants are income-related and account for 20.03% of the company's audited net profit for the most recent fiscal year. The company will classify these grants as income-related government grants in accordance with the Accounting Standards for Business Enterprises.
688553.CG ▲
Jiemian·74dRead more →
© 2026 MarketDXAsset